We conducted a cohort study to identify risk factors of chronic kidney disease (CKD) among long-term survivors of hematopoietic cell transplant (HCT). We studied 1635 patients transplanted at the Fred Hutchinson Cancer Research Center (FHCRC) between 1991 and 2002, who survived to day þ 131 after transplant and had serum creatinine measured on at least two occasions after day þ 131. CKD was defined as a glomerular filtration rate o 60 ml/min/m 2 on two occasions separated by at least 30 days between days 100 and 540 post transplant. Cox regression models estimated hazard ratios (HRs) describing associations between demographic data, clinical variables and the risk of developing CKD. A total of 376 patients (23%) developed CKD at a median of 191 days post transplant (range 131-516 days). An increased risk of CKD was associated with acute renal failure (ARF) (HR ¼ 1.7, 95% confidence interval (CI) 1.3-2.1), acute graft-vs-host disease (aGVHD) grade II (HR ¼ 2.0, 95% CI 1.4-2.9) and grades III/IV (HR ¼ 3.1, 95% CI 2.1-4.6) and chronic GVHD (HR ¼ 1.8, 95% CI 1.4-2.2). Total body irradiation (TBI) (HR ¼ 1.0, 95% CI 0.8-1.3) was not associated with an increased risk of CKD. CKD is relatively common among survivors of HCT. The presence of ARF and GVHD, but not receipt of TBI, appears to be associated with the occurrence of CKD.
Introduction
Chronic kidney disease (CKD) is common in survivors of hematopoietic cell transplant (HCT), affecting approximately 25% of adults 1 and up to 62% of children. 2 Mortality rates among transplant survivors with CKD are higher than among transplant recipients who retain normal renal function, even when controlled for co-morbidity. Among those who progress to end-stage renal disease requiring dialysis, the case fatality approaches 90%. 3 The causes of CKD after HCT are not well understood. Total body irradiation (TBI) and calcineurin inhibitor toxicity are frequently cited as possible causes of post transplant renal dysfunction. [4] [5] [6] [7] [8] [9] [10] However, early acute renal failure (ARF) and graft-vs-host disease (GVHD) may also contribute to CKD. [5] [6] [7] Of the numerous studies in the literature, few have had numbers large enough to allow for statistical modeling with adjustment for multiple potential risk factors. [4] [5] [6] [7] [8] [9] [10] The variability in incidence rates among adult and pediatric studies as well as the variability in risk factors likely reflects a lack of a standard definition of post-HCT renal disease, differences in types of transplants studied, and variable periods of follow-up.
In order to develop prevention strategies, a clearer understanding of the cause(s) of CKD after HCT is needed. We studied a cohort of 1635 patients transplanted at the Fred Hutchinson Cancer Research Center (FHCRC) from 1991 to 2002 to identify risk factors for the development of CKD.
Methods

Study population
The study cohort consists of all patients transplanted at our institution between 1991 and 2002 who survived to day þ 131 post transplant and who had sufficient long-term follow-up serum creatinine data (defined as having at least two serum creatinine measurements between days 100 and 540 post transplant, and at least one measurement within 3 months of 1 year post transplant, loss to follow-up or death, whichever came first). 11 and the Schwartz formula for children 12 ) in the range of days 100-540 post transplant, plus a GFR of o60 ml/min/1.73 m 2 for the last measurement in that time span. The time between the two abnormal measurements was a minimum of 30 days. We chose this definition to avoid including patients with transient elevations in serum creatinine and decreases in GFR. Because we wanted to study the renal injury that occurs after day þ 100 post transplant and patients had to have two serum creatinine measurements separated by a minimum of 30 days, patients had to survive to day þ 131 to be included in this cohort.
Definition of CKD
Patients with a missing or abnormally high serum creatinine at baseline (before transplant day 0) were excluded. Of 4528 patients who received their first transplant during this time period, 3436 survived to day þ 131 and 1635 patients met our inclusion criteria. A total of 1801 patients were excluded from this analysis because of a lack of serum creatinine values (n ¼ 1749), and/or a missing or abnormal baseline serum creatinine (n ¼ 95). The excluded cohort had a larger proportion of patients who had received autologous and syngeneic transplants, and those with solid tumors (predominantly breast cancer) and multiple myeloma (MM). Among the excluded patients, fewer patients received TBI, developed acute GVHD (aGVHD) or had ARF. A protocol for this analysis was approved by the Institutional Review Office of the FHCRC.
Technique of HCT All patients undergoing HCT received a conditioning regimen followed by infusion of donor hematopoietic cells. Myeloablative regimens were typically cyclophosphamidebased (with either TBI or busulfan) for allogeneic transplants; many autologous graft recipients received a regimen of busulfan/melphalan/thiotepa. 13 Non-myeloablative consisted of fludarabine and low-dose TBI.
14 The kidneys were not shielded. The day of stem cell infusion is termed 'day zero', by convention. Allogeneic graft recipients received prophylaxis against aGVHD with immunosuppressive drugs, usually cyclosporine or tacrolimus plus methotrexate. 15 Prophylaxis for infections included acyclovir for herpes simplex virus, trimethoprim/sulfamethoxazole to prevent Pneumocystic jiroveci infection, oral fluconazole for prophylaxis of candidal infection and pre-emptive ganciclovir for cytomegalovirus disease among viremic patients. [16] [17] [18] [19] Statistical analysis Cox regression modeling was used to analyze the relation between CKD and the following covariates: original diagnosis; donor type (matched sibling, non-sibling relative, or unrelated allogeneic, autologous or identical twin); intensity of conditioning regimen (myeloablative or nonmyeloablative); inclusion of TBI in the conditioning regimen; average and maximum total serum bilirubin to day þ 100; aGVHD; chronic GVHD (cGVHD); and ARF (defined as a doubling of baseline serum creatinine before day þ 60 post transplant). Indications for transplant were: (1) acute leukemias and chronic myelogenous leukemia (CML) in blast crisis or accelerated phase; (2) chronic lymphocytic leukemia, CML in chronic phase, lymphomas and myelodysplastic syndrome; (3) MM; (4) solid tumors; (5) non-malignant disorders. Cyclosporine use was not included in the model because it was closely associated with type of transplant. However, a subset analysis was performed using all patients receiving an allogeneic transplant and cyclosporine (N ¼ 1319) to determine if in this group of patients, additional risk factors, beyond cyclosporine use, could be identified for the development of CKD.
All covariates were considered as candidates for the multiple Cox regression model. As cGVHD is diagnosed after day 100, it was modeled as a time-dependent covariate. Variables were retained in the final model if considered predictors of interest (type of transplant and TBI), or if they significantly contributed to an explanation of the variability in CKD. Reported P-values are twosided, and based on the Wald statistic. No adjustments are made for multiple comparisons.
To investigate differences in risk factors for CKD between those patients who developed ARF following HCT and before their developing CKD, and those who developed de novo CKD after day þ 100, we evaluated a subset of patients who had no laboratory evidence of acute renal injury in the first 100 days post transplant. In this subset analysis, acute renal injury was defined as at least one elevated serum creatinine value (42.0 mg/dl in men, 41.8 mg/dl in women, 41.0 mg/dl in children aged 2-16 years, and 40.6 mg/dl in children aged less than 2 years) or a doubling of baseline serum creatinine in the first 100 days after transplant. The statistical methods are analogous to those described above.
Results
Demographics of study cohort
The median age of the study cohort at the time of HCT was 38.5 years, with a range of 4 months to 72.5 years. Fiftythree percent of the patients were women. Approximately 86% of patients were transplanted for hematologic malignancies. The two most common allogeneic donor types were human leukocyte antigen (HLA)-matched sibling (40%) and HLA-matched unrelated donor (34%). Ninety-five percent of transplant conditioning regimens were myeloablative and 58% of patients received TBI as part of their conditioning regimen.
CKD developed in 376 of 1635 patients (23%). The median time to development of CKD was 191 days post transplant with a range of 131-516 days. The median number of days between the two high serum creatinine values was 56, with a range of 31-413 days.
Risk factors for CKD
A multivariable Cox regression model was created using all patients in the study cohort (n ¼ 1635) and adjusting for demographic data and baseline characteristics, including original diagnosis, donor type, transplant type and transplant year (Table 1) . In this analysis, there was no increased risk of CKD in those patients who received TBI (Table 2) . In a multivariable analysis that included risk factors defined by events that occurred during the first 100 days after HCT, aGVHD grade II (HR ¼ 2.0, 95% CI 1.4-2.9) and grades III/IV (HR ¼ 3.1, 95% CI 2.1-4.6) were associated with an increased risk of CKD compared to those patients with grade 0 or I aGVHD. CKD incidence was relatively high in patients who developed ARF (HR ¼ 1.7, 95% CI 1.3-2.1) and in those with cGVHD (HR ¼ 1.8, 95% CI 1.4-2.2). Similar hazard ratios were found when the analysis was limited to patients who received allogeneic transplants and cyclosporine prophylaxis (Table 3) . Additionally, in the allografts, a nonmyeloablative transplant was associated with an increased risk of CKD (HR ¼ 1.9, 95% CI 1.2-3.0).
Subset analysis of patients without early renal injury
An analysis was performed among those patients without laboratory evidence of early renal injury to day þ 100 (n ¼ 972). Among the 972 patients, 167 (17.2%) later developed CKD. CKD occurred at a median of 236 days post transplant, with a range of 131-504 days. By multivariable analysis, only older age (HR ¼ 15.0, 95% CI 3.7-61.3), female gender (HR ¼ 1.7, 95% CI 1.2-2.3), aGVHD grade II (HR ¼ 2.0, 95% CI 1.1-3.6) and grade III/IV (HR ¼ 3.8, 95% CI 2.0-7.2) and cGVHD (HR ¼ 1.6, 95% CI 1.1-2.4) were associated with risk of CKD in this subset of patients. Once again, the receipt of TBI was not associated with an increased risk of CKD (HR ¼ 0.9, 95% CI 0.6-1.3).
Discussion
This is the largest cohort study to date to identify risk factors for CKD in patients after HCT. CKD was relatively common, affecting 23% of long-term survivors of HCT for whom renal function was evaluated. The risk of CKD varied by type of transplant and was lower among autologous transplant recipients and higher among patients receiving a non-myeloablative, allogeneic transplant. We were able to identify risk factors for the development of CKD both in the presence and the absence of early acute renal damage. Not surprisingly, the risk of CKD was higher among transplant survivors who had developed ARF in the aftermath of transplant; however, other risk factors for CKD were similar whether or not ARF had occurred. That is, the risk of CKD was increased for patients who developed aGVHD grades II-IV or cGVHD Chronic kidney disease after HCT S Hingorani et al independent of whether ARF developed after transplant.
Receipt of TBI as a component of the conditioning regimen was not associated with increased risk. An earlier study of 79 patients who underwent HCT also observed an increased risk of CKD (defined as three consecutive serum creatinine measurements in excess of 110 mmol/l) in patients who had developed GVHD (relative risk ¼ 3.5, 95% CI 1.4-9.0). 7 The strong association with GVHD seen in that study and the identification of both aGVHD and cGVHD as risk factors for the development of CKD in our study, suggest that either the kidney is a direct target organ of GVHD via T-cell-mediated renal damage or susceptible to the chronic systemic inflammatory state of GVHD leading to CKD. A third possibility is that chronic exposure to calcinuerin inhibitors, such as cyclosporine or tacrolimus that are used as prophylaxis for GVHD, leads to CKD. These are not mutually exclusive hypotheses as T-cell-mediated injury in GVHD is intertwined with cytokine effects 20 and the effects of cyclosporine may be potentiated in the presence of a chronic inflammatory state. 21 In an autopsy study of renal pathology in 26 autologous and allogeneic HCT patients, renal tubulitis identical to that seen in renal allograft rejection was present in 67% of patients. 22 In a mouse model of GVHD in which the kidneys were examined, venulitis, endothelialitis and tubulitis were present as early as 2 weeks post transplant with progression of the lymphocytic inflammatory process noted at 6 months. The inflammatory and cytokine cascade that accompanies GVHD may also affect the kidney without invoking the T-cell injury that is present in GVHD involving skin, gut and liver. 23, 24 In support of this hypothesis, several studies have demonstrated that elevations in plasma cytokine levels correlated with development of post transplant complications and organ dysfunction in the HCT population. 25, 26 In animal models of GVHD, tissue destruction of aGVHD does not require alloantigen expression on target epithelium for cellular cytotoxicity but can be mediated by inflammatory cytokines. 27 In addition to T-cell activation and cytokine release in aGVHD, cGVHD also involves the activation of B cells and production of cytokines including transforming growth factor (TGF)-b1. 28 TGF-b1 is important for collagen synthesis and matrix deposition in the kidney and other organs 29, 30 and may also be important in the development of cyclosporine nephropathy in non-renal transplant patients. 31 The effects of cyclosporine on the kidney can be potentiated by increases in the production of TGF-b. 32 Our data do not allow us to differentiate between T-cell-or cytokine-mediated renal injury or cumulative toxicity of calcineurin inhibitors.
We were unable to distinguish whether cGVHD per se or its treatment increased the risk of CKD in this cohort of patients. However, when adjusting for risk factors defined by events after transplant in the subgroup of patients who received allografts and cyclosporine, the association between GVHD and CKD was strong, suggesting that GVHD is an independent predictor of later CKD. Patients do develop CKD after transplant in the absence of cyclosporine therapy. 2, 7, 10, 33, 34 Cyclosporine is a known nephrotoxin with varied effects on the kidney. 35 Although cyclosporine has been associated with CKD in some studies of solid organ transplant, 36,37 a comprehensive study of approximately 69 000 patients receiving heart, lung, liver, intestine and combined heart-lung transplants, showed that cyclosporine use at initial hospitalization was associated with only a slightly increased risk of developing CKD after organ transplant (HR ¼ 1.24, 95% CI 1.17-1.30). 38 TBI is frequently suggested as a possible cause of CKD after HCT, 5, 9, 33, [39] [40] [41] although the data are not consistent. 6, 8, 34, 42 CKD has been thought to be synonymous with radiation nephritis or hemolytic uremic syndrome secondary to either TBI or calcinuerin inhibitors. In a prospective study using renal shielding, a trend toward decreased incidence of CKD was observed in the shielded vs the unshielded groups (0-10% vs 18%, respectively). 39, 40 In a small study of 79 patients, increasing doses of radiation increased the probability of renal insufficiency at 18 months. 7 However, in a more recent study by the same group, patients who received a lower dose of TBI because of renal shielding actually had a greater impairment in GFR at 4 months compared to patients who received higher TBI doses (the effects were no longer apparent by 12 months after transplant). 8 Our data, from a much larger patient cohort, suggest that irrespective of dose, TBI is not an independent risk factor for CKD in the cohort as a whole, or among patients who evinced no evidence of acute renal injury during the first 60 days after HCT.
We found that development of ARF before transplant day þ 60 was associated with an increased risk of CKD among long-term survivors. However, approximately 17% of patients in our study cohort developed CKD without any laboratory evidence of early renal injury. The risk factors associated with CKD in both those with and without early renal injury were similar suggesting that the mechanism(s) of injury is the same, but perhaps becomes evident at different time points. It may be that some patients never recover from their ARF and simply maintain their degree of renal dysfunction, whereas others progress to CKD.
Patients receiving a non-myeloablative transplant were at increased risk of CKD. This is most likely because older, often sicker patients are given these types of transplants and they often have co-morbid conditions placing them at increased risk of kidney injury. Although the definition differs, an increased incidence of CKD has been described in the non-myeloablative transplant population compared to myeloablative transplant patients. 43 Despite the inclusion of a large number of patients and the availability of excellent clinical demographic data, there are some limitations to this study. The majority of patients were discharged back to the care of their local physicians and serum creatinine was not always measured at regular intervals and/or the data were not reported back to our institution. We therefore restricted our analyses to those patients with adequate serum creatinine measurements, and required at least two serum creatinine measurements after day 100. The exclusion of a large number of patients because of insufficient measurements could lead to an overestimation or underestimation of the incidence of CKD. Data on other potential contributors to development of renal disease such as hypertension, hyperlipidemia, diabetes and recurrent use of nephrotoxic medications were not available for analysis.
CKD developed commonly in our HCT population. The finding of an association between CKD and aGVHD and cGVHD suggests that either T-cell-mediated tubular injury or the inflammatory and cytokine milieu of GVHD are the proximate causes of chronic renal damage. The effect of GVHD appears to be independent of early cyclosporine use. TBI did not play a role in the development of CKD in this patient population. Although much of the emphasis in management of these patients has been on reducing the exposure to or dose of cyclosporine to prevent CKD, we speculate that prevention of aGVHD and cGVHD or altering the cytokine and inflammatory response of GVHD will do more to reduce the incidence of CKD following HCT.
